Mar 7, 2022Sandwalk to present and actively participate in Probiota 2022 in CopenhagenLuis Gosálbez, Managing Director and Co-Founder, will be presenting Sandwalk’s latest market analysis on postbiotics in food, feed,...
Dec 1, 2021Sanofi to acquire skin microbiome drug developer biotech Origimm French pharmaceutical giant Sanofi has inked the acquisition of Origimm Biotechnology GmbH, an Austrian biotech developing therapies...
Dec 1, 2021Sandwalk's Bactheriophage Drug Development Report published on The Microbiome TimesWe are pleased to announce that our Bactheriophage Drug Development Report is now available at the Microbiome Times. The report contains...
Nov 17, 2021BioNTech acquires bacteriophage company PhagoMedBioNTech has announced it has completed the acquisition of the bacteriophage therapy, Austrian company PhagoMed GmbH to “increase its...
Sep 7, 2021Sandwalk to present at the upcoming Probiotics, Prebiotics & New Foods event, Sept 12-14Sandwalk Bioventures´ Managing Director Dr. Luis Gosálbez will be speaking at the upcoming Probiotics, Prebiotics & New Foods event in...
Aug 31, 2021Sandwalk ranked as one of the 31 Best Madrid-Based Venture Capital Firms 2021 by Daily FinanceSandwalk BioVentures, the specialty strategy, innovation, regulatory and management consulting firm focused on microbiome has been listed...
